Tweet
Cannell Peter B & Co. Inc. decreased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 11.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,134 shares of the biopharmaceutical company's stock after selling 2,885 shares during the period. Cannell Peter B & Co. Inc.'s holdings in Bristol-Myers Squibb were worth $1,280,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in BMY. MUFG Securities EMEA plc acquired a new stake in shares of Bristol-Myers Squibb in the second quarter valued at about $134,854,000. Los Angeles Capital Management & Equity Research Inc. lifted its stake in shares of Bristol-Myers Squibb by 154.3% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 1,900,564 shares of the biopharmaceutical company's stock valued at $105,177,000 after purchasing an additional 1,153,130 shares during the period. Argent Capital Management LLC lifted its stake in shares of Bristol-Myers Squibb by 353.6% in the first quarter. Argent Capital Management LLC now owns 1,162,788 shares of the biopharmaceutical company's stock valued at $73,546,000 after purchasing an additional 906,415 shares during the period. Unigestion Holding SA acquired a new stake in shares of Bristol-Myers Squibb in the second quarter valued at about $38,239,000. Finally, Rock Springs Capital Management LP lifted its stake in shares of Bristol-Myers Squibb by 1,200.0% in the first quarter. Rock Springs Capital Management LP now owns 650,000 shares of the biopharmaceutical company's stock valued at $41,113,000 after purchasing an additional 600,000 shares during the period. Hedge funds and other institutional investors own 70.89% of the company's stock. Get Bristol-Myers Squibb alerts:
BMY has been the subject of several recent analyst reports. Barclays reduced their price objective on shares of Bristol-Myers Squibb from $65.00 to $55.00 and set an "equal weight" rating for the company in a research note on Friday, April 27th. ValuEngine downgraded shares of Bristol-Myers Squibb from a "hold" rating to a "sell" rating in a report on Wednesday, May 2nd. BMO Capital Markets restated a "sell" rating and set a $47.00 target price on shares of Bristol-Myers Squibb in a report on Thursday, April 26th. Jefferies Financial Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the company a "hold" rating in a report on Sunday, July 15th. Finally, Atlantic Securities upgraded shares of Bristol-Myers Squibb from an "underweight" rating to a "neutral" rating and set a $57.00 target price for the company in a report on Wednesday, August 8th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have assigned a buy rating to the company's stock. Bristol-Myers Squibb presently has an average rating of "Hold" and a consensus target price of $63.11.
NYSE:BMY opened at $61.11 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.40 and a debt-to-equity ratio of 0.46. Bristol-Myers Squibb Co has a twelve month low of $49.96 and a twelve month high of $70.05. The stock has a market cap of $96.94 billion, a price-to-earnings ratio of 20.30, a price-to-earnings-growth ratio of 1.50 and a beta of 1.02.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.87 by $0.14. The business had revenue of $5.70 billion during the quarter, compared to the consensus estimate of $5.48 billion. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The company's quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.74 earnings per share. research analysts forecast that Bristol-Myers Squibb Co will post 3.62 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Wednesday, August 1st. Stockholders of record on Friday, July 6th were issued a dividend of $0.40 per share. The ex-dividend date was Thursday, July 5th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.62%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 53.16%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Article: Closed-End Mutual Funds (CEFs)
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY). Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter 